The English Court has strengthened its collaboration with the Spanish Association Against Cancer (AECC) by committing to contribute one million euros over five years for a research project on breast cancer, the agreement for which was signed in February 2020.
The research focuses on personalized immunotherapy and has an estimated duration of five years, as indicated by the company in a press release. The project is being carried out by a multidisciplinary team from hospitals Barcelona Clinic, October 12 in Madrid, El Vall d’Gebron Institute of Oncology and the University Clinic of Navarra.
The study is led by the head of the Oncology service at the Hospital Clinic of Barcelona, Alex Pratand consists of activating the patient’s own immune system so that it is capable of recognizing and eliminating tumor cells.
Three projects in collaboration
El Corte Inglés has already financed three projects in collaboration with the AECC. The company began supporting, in 2014, a project that focused on the investigation of new therapeutic alternatives to reduce the risk of recurrence of hereditary breast cancer treated by surgery and chemotherapy.
The second project financed by the company began in 2017 and aimed to design a predictive test that would allow a precision medicine, designed for each patient. This investigation ended at the end of 2021.
In 2019, the third project fully financed by El Corte Inglés was launched, focused on hormone therapy, with an expected duration of up to four years.
In total, the company has allocated more than 1 million euros in the last seven years for research projects promoted by the AECC, which reflects El Corte Inglés’ commitment to tackling the most harmful effects of this disease.